AUXLY CANNABIS WKN: A2JNSX ISIN: CA05335P1099 Kürzel: XLY Forum: Aktien Thema: Hauptdiskussion

Oh, großer wichel, danke für deine tausendste Wiederholung deiner bedeutungslosen Meinung.

"Keine Erwartung" sollte da stehen.

Phenox: nein, ich habe Erwartung. Eine gewissenhafte Schätzung ist meiner Ansicht nach unmöglich. Zu viele Dinge sind ungewiss und die Präsentationen sind intransparent. Selbst das Management traut sich nicht, eine Schätzung auszusprechen. Man sollte daher Erwartungen am untersten Ende der Angaben ansetzen. Und... heute ist Quartalsschluss. Es liegen also wichtigere Zahlen als irgendwelche Phantasien über bisher nicht vorhandene Umsätze an.

Leute ich bin auch im Minus, aber wir können uns beschweren wenn das Ding zu gemacht hat oder in 5 Jahren hier immer noch so steht. Der Rest liegt an der Politik des Unternehmens und den Leuten die die Ware kaufen

Au man... das es nicht einfach ist ist mir klar. Dennoch könnt ihr doch etwas erwarten, es gibt Vorräte... es gibt diese Farmergeschichte zur belieferung von dosecann. Daraus werden Produkte entstehen und diese sollen ja wohl dann aussagegemäß auch ab 2.0 verkauft werden (darauf setzt das Auxly Management) Hast du wichel, oder auch andere, dazu eine Erwartung? Und bitte nicht schreiben „es ist schwer“ das weiß ich selbst

Phenox, eine Umsatzschätzung ist schwierig bis unmöglich. Die Datenlage ist sehr schleierhaft gehalten und eine Schätzung wäre nicht mehr, als ein Schuss ins Blaue. Ich rechne damit, dass die Zahlen deutlich schlechter ausfallen, als gemeinhin von den Glücksrittern erhofft.

FabS, die Nachricht wurde 4 Beiträge vor Deiner Anfrage bereits gepostet und ist nicht neu. Die angekündigte Wandelanleihe ist ausgegeben...

VANCOUVER, British Columbia, Sept. 25, 2019 (GLOBE NEWSWIRE) — Auxly Cannabis Group Inc. (TSX.V: XLY) (OTCQX: CBWTF) (“Auxly” or the “Company”) today announced that its transaction (the “Transaction”) with Imperial Brands PLC (“Imperial Brands”) has closed. As announced on July 25, 2019, Imperial Brands invested C$123 million by way of a debenture pursuant to the Transaction, which is convertible into 19.9% ownership of Auxly. Imperial Brands grants Auxly global licenses to its vaping technology, access to its vapor innovation business, Nerudia, and will use Auxly as its exclusive partner for the future development, manufacture, commercialization, sale and distribution of cannabis products of any kind anywhere in the world. “We are delighted to announce the closing of this transaction to formally mark the start of our strategic partnership with Imperial Brands,” said Hugo Alves, Chief Executive Officer of Auxly. “We believe there is considerable opportunity for growth and value creation for both companies. We are looking forward to working with the incredibly strong team at Imperial Brands as we prepare to launch our portfolio of branded derivative products, formulated and manufactured at our subsidiary, Dosecann, later this year. We welcome Imperial Brands’ experience and expertise on our Board and on our Safety Committee to help ensure that all of our branded products are produced to Dosecann’s exacting standards of quality, safety and efficacy and earn the trust of Canadian consumers.” In connection with the closing of the Transaction, Auxly’s Board has added Conrad Tate as a new director and John Downing as a non-voting observer. They join Auxly’s existing directors: Chuck Rifici; Hugo Alves; Troy Grant; and Genevieve Young. Conrad Tate, Corporate Development Director, Imperial Brands Conrad joined Imperial Brands in 1998 having previously worked for a large regional law firm. He has held a number of senior legal and commercial roles in the business and was appointed Corporate Development Director in 2010. Conrad has played a key role in a number of significant transactions over the years, including the acquisition of Altadis, Commonwealth Brands, assets purchased by Imperial as part of the Reynolds American takeover of Lorillard and Nerudia. He has led Imperial Brands’ investigation, analysis and entry into the legal cannabis sector and is currently leading a major divestment program for Imperial Brands, which will realize proceeds of up to £2 billion. John Downing, Company Secretary, Imperial Brands John, a qualified solicitor, joined Imperial Brands in 2005 having previously worked for the law firm Linklaters. He has had a number of senior legal roles in Imperial Brands including playing a leading role in the Altadis acquisition and becoming Head of Group Legal in 2010. He has considerable experience in managing key corporate projects related to financing, business development and other commercial matters. In addition to his Group Company Secretary role at Imperial Brands, John also has responsibility for the Group’s governance, Code of Conduct, security and information security. “I’m thrilled to be closing this transaction with Auxly, a dynamic, highly skilled organization that has all the ingredients required for delivering success in the branded derivatives market and beyond,” said Conrad Tate, Corporate Development Director, Imperial Brands. “We’re excited by the opportunities this partnership offers and look forward to working with Auxly to build its business and realize its significant future growth potential.”

https://ryghub.com/2019/09/auxly-closes-c123-million-investment-and-rd-partnership-with-imperial-brands-and-strengthens-its-board/

Was?

Bin ich blind oder hat keiner den 123 Mio Deal gepostet?

Hallo zusammen, hatte nach euren Einschätzungen zur Umsatzprognose 2020 gefragt; wäre für interessant. Jetzt traut euch mal. Danke!

Was für Kennzahlen?

Wo bekommt ihr verlässliche Informationen über die Kennzahlen her?

Auxly Cannabis Group Inc.'s transaction with Imperial Brands PLC has closed. As announced on July 25, 2019, Imperial Brands invested C$123 million by way of a debenture pursuant to the Transaction, which is convertible into 19.9% ownership of Auxly. Imperial Brands grants Auxly global licenses to its vaping technology, access to its vapor innovation business, Nerudia, and will use Auxly as its exclusive partner for the future development, manufacture, commercialization, sale and distribution of cannabis products of any kind anywhere in the world. "We are delighted to announce the closing of this transaction to formally mark the start of our strategic partnership with Imperial Brands," said Hugo Alves, Chief Executive Officer of Auxly. "We believe there is considerable opportunity for growth and value creation for both companies. We are looking forward to working with the incredibly strong team at Imperial Brands as we prepare to launch our portfolio of branded derivative products, formulated and manufactured at our subsidiary, Dosecann, later this year. We welcome Imperial Brands' experience and expertise on our Board and on our Safety Committee to help ensure that all of our branded products are produced to Dosecann's exacting standards of quality, safety and efficacy and earn the trust of Canadian consumers." In connection with the closing of the Transaction, Auxly's Board has added Conrad Tate as a new director and John Downing as a non-voting observer. They join Auxly's existing directors: Chuck Rifici; Hugo Alves; Troy Grant; and Genevieve Young. Conrad Tate, Corporate Development Director, Imperial Brands Conrad joined Imperial Brands in 1998 having previously worked for a large regional law firm. He has held a number of senior legal and commercial roles in the business and was appointed Corporate Development Director in 2010. Conrad has played a key role in a number of significant transactions over the years, including the acquisition of Altadis, Commonwealth Brands, assets purchased by Imperial as part of the Reynolds American takeover of Lorillard and Nerudia. He has led Imperial Brands' investigation, analysis and entry into the legal cannabis sector and is currently leading a major divestment program for Imperial Brands, which will realize proceeds of up to pounds sterling2 billion. John Downing, Company Secretary, Imperial Brands John, a qualified solicitor, joined Imperial Brands in 2005 having previously worked for the law firm Linklaters. He has had a number of senior legal roles in Imperial Brands including playing a leading role in the Altadis acquisition and becoming Head of Group Legal in 2010. He has considerable experience in managing key corporate projects related to financing, business development and other commercial matters. In addition to his Group Company Secretary role at Imperial Brands, John also has responsibility for the Group's governance, Code of Conduct, security and information security. "I'm thrilled to be closing this transaction with Auxly, a dynamic, highly skilled organization that has all the ingredients required for delivering success in the branded derivatives market and beyond," said Conrad Tate, Corporate Development Director, Imperial Brands. "We're excited by the opportunities this partnership offers and look forward to working with Auxly to build its business and realize its significant future growth potential."

Wagt jemand von euch eine Umsatzprognose für 2020? Da wird ja teilweise von 150 - 180 Mio. CAD gesprochen. Was sind eure Erwartungen und auf welche Basis? Ich könnte mir so 12 Mio. in Q1 2020, 18 Mio. in Q2 2020, Q3 25 Mio. Q4 35 - 40 Mio. vorstellen. D.h. ca. 95 Mio. CAD für 2020 total. Denke ab Q3 kann sicher mehr gehen, wegen Sunens.Uruguay hab ich nicht berücksichtigt, das ist politisch und ich habe da kein Gefühl. Danke für eure Einschätzungen/ Anmerkungen